RARE — Ultragenyx Pharmaceutical Inc.
RARE dilution and offerings
- Float: 92.9M shares
🔔 Alert me if RARE files an offering or S-3
$16.63+2.02%
Last close: · regular session
Pre-market $16.02 -3.67% ·
Last 60 sessions
Float: 92.9M shares. Latest SEC filing: 8-K on Nov 3, 2026. RARE closed at $16.63 (+2.02%) on Nov 3, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for RARE in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 1,294
- Website: https://www.ultragenyx.com
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Latest SEC filings for RARE
Latest RARE news
- Ultragenyx outlines 2027 profitability plan with R&D under $350M and SG&A under $375M following GTX-102 discontinuation Read article
- Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates Read article
- Ultragenyx granted conditional U.K. nod for Dojolvi Read article
- RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week Read article
- Ultragenyx to sell Fayuvi FDA priority review voucher for $203M Read article
- Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? Read article
- Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million Read article
- Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.